126 related articles for article (PubMed ID: 37867340)
1. Clinical Efficacy of Bushen Yiqi Fuzheng Decoction Combined with Sunitinib in the Treatment of Postoperative Patients with Renal Cell Carcinoma and Its Influence on Their Immune Function.
Zhang L; Liu L; Zhao L; Yuan X; Wang Y; Yang J
Arch Esp Urol; 2023 Sep; 76(7):538-547. PubMed ID: 37867340
[TBL] [Abstract][Full Text] [Related]
2. Effect of Psychological Intervention Combined with Dietary Guidance on Quality of Life and Long-Term Efficacy of Bushen Quyu Decoction in Treatment of Patients with Advanced Ovarian Cancer.
Liu D; Shi G; Yin C; Liu Z; Yang A
Evid Based Complement Alternat Med; 2021; 2021():1075513. PubMed ID: 34733335
[TBL] [Abstract][Full Text] [Related]
3. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Sunitinib therapy on immune function of patients with advanced renal cell carcinoma].
Xian P; Li Y; Zhou H; Luo H; Liu N; Dai JY
Zhonghua Wai Ke Za Zhi; 2016 Oct; 54(10):741-745. PubMed ID: 27686636
[No Abstract] [Full Text] [Related]
6. A Clinical Study on the Use of Yiqi Yangxue Decoction Combined with Chemotherapy to Promote Rapid Postoperative Recovery in Patients with Non-Small Cell Lung Cancer.
Liang J; Wang Y; Zheng L; Mei H
Emerg Med Int; 2022; 2022():7073893. PubMed ID: 36119912
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy: a meta-analysis.
Liu M; Wang H; Lv P
Am J Transl Res; 2023; 15(6):3815-3824. PubMed ID: 37434822
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
9. Clinical observation of Yiqi Qingdu prescription on the treatment of intermediate-stage and advanced non-small-cell lung cancer.
Liang Q; Tang X; Yu J; Xiong M; Zhu H; Xiong L; Zeng R; Yu P
J Tradit Chin Med; 2021 Apr; 41(2):308-315. PubMed ID: 33825412
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Bushen Yiqi Huayu Decoction on Ovarian Reserve and Inflammatory Factors in Patients after Hysterectomy plus Salpingectomy.
Zhang J; Zhang L; Cao L
Evid Based Complement Alternat Med; 2022; 2022():5866685. PubMed ID: 35280513
[TBL] [Abstract][Full Text] [Related]
12. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
13. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
[TBL] [Abstract][Full Text] [Related]
14. Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Lai X; Wang A
Comput Intell Neurosci; 2022; 2022():6336107. PubMed ID: 36052044
[TBL] [Abstract][Full Text] [Related]
15. [Effect of modified Buzhong Yiqi decoction combined with pelvic floor muscle exercise-biofeedback-electrical stimulation on early stage postpartum pelvic floor dysfunction].
Chen Z; Huang H; Chen QY
Zhongguo Zhong Yao Za Zhi; 2018 Jun; 43(11):2391-2395. PubMed ID: 29945396
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC.
Guo J; Guo J; Cheng B; Sun X; Zhang H; Ma J
J Healthc Eng; 2022; 2022():7875627. PubMed ID: 35299680
[TBL] [Abstract][Full Text] [Related]
17. Effects of Angelica Fritillaria Kushen Pill on Renal Function and Immune Function after Laparoscopic Radical Nephrectomy for Patients with Renal Carcinoma.
Wang X; Liu J; Zhou P; Han Z; Meng Z; Yang H
J Healthc Eng; 2022; 2022():4082121. PubMed ID: 35368912
[TBL] [Abstract][Full Text] [Related]
18. [Expression and pathological mechanism of MMP-9 and HIF-2α in CD133(+) lung cancer stem cells].
Gao Y; Feng J; Wu L; Zhan S; Sun J
Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(32):2607-11. PubMed ID: 26711609
[TBL] [Abstract][Full Text] [Related]
19. Effects of Buzhong Yiqi Decoction Combined with THP Bladder Perfusion on Postoperative Efficacy in Patients with Bladder Cancer.
Wang Y; Zhang Y; Liu Z; Li Q; Jin H
Evid Based Complement Alternat Med; 2021; 2021():3685213. PubMed ID: 34804176
[TBL] [Abstract][Full Text] [Related]
20. Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1.
Yan J; Li D; Liu Q; Xie Y
Comput Math Methods Med; 2022; 2022():7982023. PubMed ID: 35572824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
